Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

VEGFC Antibody Therapy Drives Differentiation of AML.

Kampen KR, Scherpen FJG, Mahmud H, Ter Elst A, Mulder AB, Guryev V, Verhagen HJMP, De Keersmaecker K, Smit L, Kornblau SM, De Bont ESJM.

Cancer Res. 2018 Oct 15;78(20):5940-5948. doi: 10.1158/0008-5472.CAN-18-0250. Epub 2018 Sep 5.

PMID:
30185550
2.

The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.

Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt SM, Vermeersch P, De Keersmaecker K.

Leukemia. 2018 Jun 21. doi: 10.1038/s41375-018-0176-z. [Epub ahead of print]

PMID:
29930300
3.

Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.

De Bie J, Demeyer S, Alberti-Servera L, Geerdens E, Segers H, Broux M, De Keersmaecker K, Michaux L, Vandenberghe P, Voet T, Boeckx N, Uyttebroeck A, Cools J.

Leukemia. 2018 Jun;32(6):1358-1369. doi: 10.1038/s41375-018-0127-8. Epub 2018 Apr 18.

4.

Ribosomal proteins: a novel class of oncogenic drivers.

Sulima SO, De Keersmaecker K.

Oncotarget. 2017 Sep 11;8(52):89427-89428. doi: 10.18632/oncotarget.20802. eCollection 2017 Oct 27. No abstract available.

5.

How Ribosomes Translate Cancer.

Sulima SO, Hofman IJF, De Keersmaecker K, Dinman JD.

Cancer Discov. 2017 Oct;7(10):1069-1087. doi: 10.1158/2159-8290.CD-17-0550. Epub 2017 Sep 18. Review.

6.

The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.

Girardi T, Vereecke S, Sulima SO, Khan Y, Fancello L, Briggs JW, Schwab C, de Beeck JO, Verbeeck J, Royaert J, Geerdens E, Vicente C, Bornschein S, Harrison CJ, Meijerink JP, Cools J, Dinman JD, Kampen KR, De Keersmaecker K.

Leukemia. 2018 Mar;32(3):809-819. doi: 10.1038/leu.2017.225. Epub 2017 Jul 24.

7.

Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma.

Hofman IJF, Patchett S, van Duin M, Geerdens E, Verbeeck J, Michaux L, Delforge M, Sonneveld P, Johnson AW, De Keersmaecker K.

Haematologica. 2017 Aug;102(8):e317-e320. doi: 10.3324/haematol.2016.162198. Epub 2017 Apr 20. No abstract available.

8.

Synergistic antileukemic therapies in NOTCH1-induced T-ALL.

Sanchez-Martin M, Ambesi-Impiombato A, Qin Y, Herranz D, Bansal M, Girardi T, Paietta E, Tallman MS, Rowe JM, De Keersmaecker K, Califano A, Ferrando AA.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2006-2011. doi: 10.1073/pnas.1611831114. Epub 2017 Feb 7.

9.

The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types.

Fancello L, Kampen KR, Hofman IJ, Verbeeck J, De Keersmaecker K.

Oncotarget. 2017 Feb 28;8(9):14462-14478. doi: 10.18632/oncotarget.14895.

10.

The genetics and molecular biology of T-ALL.

Girardi T, Vicente C, Cools J, De Keersmaecker K.

Blood. 2017 Mar 2;129(9):1113-1123. doi: 10.1182/blood-2016-10-706465. Epub 2017 Jan 23. Review.

11.

RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.

Hofman IJF, van Duin M, De Bruyne E, Fancello L, Mulligan G, Geerdens E, Garelli E, Mancini C, Lemmens H, Delforge M, Vandenberghe P, Wlodarska I, Aspesi A, Michaux L, Vanderkerken K, Sonneveld P, De Keersmaecker K.

Leukemia. 2017 Aug;31(8):1706-1714. doi: 10.1038/leu.2016.370. Epub 2016 Dec 2.

12.

Ribosomal RNA analysis in the diagnosis of Diamond-Blackfan Anaemia.

Quarello P, Garelli E, Carando A, Mancini C, Foglia L, Botto C, Farruggia P, De Keersmaecker K, Aspesi A, Ellis SR, Dianzani I, Ramenghi U.

Br J Haematol. 2016 Mar;172(5):782-5. doi: 10.1111/bjh.13880. Epub 2016 Jan 13.

PMID:
26763766
13.

Impact of Denture Cleaning Method and Overnight Storage Condition on Denture Biofilm Mass and Composition: A Cross-Over Randomized Clinical Trial.

Duyck J, Vandamme K, Krausch-Hofmann S, Boon L, De Keersmaecker K, Jalon E, Teughels W.

PLoS One. 2016 Jan 5;11(1):e0145837. doi: 10.1371/journal.pone.0145837. eCollection 2016.

14.

A novel mouse model provides insights into the neutropenia associated with the ribosomopathy Shwachman-Diamond syndrome.

De Keersmaecker K.

Haematologica. 2015 Oct;100(10):1237-9. doi: 10.3324/haematol.2015.133777. No abstract available.

15.

T-ALL: ALL a matter of Translation?

Girardi T, De Keersmaecker K.

Haematologica. 2015 Mar;100(3):293-5. doi: 10.3324/haematol.2014.118562. No abstract available.

16.

Ribosomopathies and the paradox of cellular hypo- to hyperproliferation.

De Keersmaecker K, Sulima SO, Dinman JD.

Blood. 2015 Feb 26;125(9):1377-82. doi: 10.1182/blood-2014-10-569616. Epub 2015 Jan 9.

17.

Bypass of the pre-60S ribosomal quality control as a pathway to oncogenesis.

Sulima SO, Patchett S, Advani VM, De Keersmaecker K, Johnson AW, Dinman JD.

Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5640-5. doi: 10.1073/pnas.1400247111. Epub 2014 Mar 31.

18.

Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia.

Atak ZK, Gianfelici V, Hulselmans G, De Keersmaecker K, Devasia AG, Geerdens E, Mentens N, Chiaretti S, Durinck K, Uyttebroeck A, Vandenberghe P, Wlodarska I, Cloos J, Foà R, Speleman F, Cools J, Aerts S.

PLoS Genet. 2013;9(12):e1003997. doi: 10.1371/journal.pgen.1003997. Epub 2013 Dec 19.

19.

NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.

De Keersmaecker K, Porcu M, Cox L, Girardi T, Vandepoel R, de Beeck JO, Gielen O, Mentens N, Bennett KL, Hantschel O.

Haematologica. 2014 Jan;99(1):85-93. doi: 10.3324/haematol.2013.088674. Epub 2013 Jul 19.

20.

Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia.

Van Vlierberghe P, Ambesi-Impiombato A, De Keersmaecker K, Hadler M, Paietta E, Tallman MS, Rowe JM, Forne C, Rue M, Ferrando AA.

Blood. 2013 Jul 4;122(1):74-82. doi: 10.1182/blood-2013-03-491092. Epub 2013 May 17.

21.

Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.

De Keersmaecker K, Atak ZK, Li N, Vicente C, Patchett S, Girardi T, Gianfelici V, Geerdens E, Clappier E, Porcu M, Lahortiga I, Lucà R, Yan J, Hulselmans G, Vranckx H, Vandepoel R, Sweron B, Jacobs K, Mentens N, Wlodarska I, Cauwelier B, Cloos J, Soulier J, Uyttebroeck A, Bagni C, Hassan BA, Vandenberghe P, Johnson AW, Aerts S, Cools J.

Nat Genet. 2013 Feb;45(2):186-90. doi: 10.1038/ng.2508. Epub 2012 Dec 23.

22.

High accuracy mutation detection in leukemia on a selected panel of cancer genes.

Kalender Atak Z, De Keersmaecker K, Gianfelici V, Geerdens E, Vandepoel R, Pauwels D, Porcu M, Lahortiga I, Brys V, Dirks WG, Quentmeier H, Cloos J, Cuppens H, Uyttebroeck A, Vandenberghe P, Cools J, Aerts S.

PLoS One. 2012;7(6):e38463. doi: 10.1371/journal.pone.0038463. Epub 2012 Jun 4.

23.

Novel insights on TLX1 function in T-ALL pave the way towards differentiation therapy.

De Keersmaecker K.

Haematologica. 2012 Jun;97(6):795. doi: 10.3324/haematol.2012.070227. No abstract available.

24.

Rearrangement of NOTCH1 or BCL3 can independently trigger progression of CLL.

De Keersmaecker K, Michaux L, Bosly A, Graux C, Ferreiro JF, Vandenberghe P, Cools J, Wlodarska I.

Blood. 2012 Apr 19;119(16):3864-6. doi: 10.1182/blood-2011-10-388124. No abstract available.

25.

Targeting nonclassical oncogenes for therapy in T-ALL.

Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K, Kashishian A, Thompson MA, Castillo M, Cordon-Cardo C, Davé UP, Ferrando A, Lannutti BJ, Diacovo TG.

Cancer Cell. 2012 Apr 17;21(4):459-72. doi: 10.1016/j.ccr.2012.02.029.

26.

An activating intragenic deletion in NOTCH1 in human T-ALL.

Haydu JE, De Keersmaecker K, Duff MK, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Ferrando A.

Blood. 2012 May 31;119(22):5211-4. doi: 10.1182/blood-2011-10-388504. Epub 2012 Apr 17.

27.

Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia.

Porcu M, Kleppe M, Gianfelici V, Geerdens E, De Keersmaecker K, Tartaglia M, Foà R, Soulier J, Cauwelier B, Uyttebroeck A, Macintyre E, Vandenberghe P, Asnafi V, Cools J.

Blood. 2012 May 10;119(19):4476-9. doi: 10.1182/blood-2011-09-379958. Epub 2012 Mar 21.

28.

Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.

Della Gatta G, Palomero T, Perez-Garcia A, Ambesi-Impiombato A, Bansal M, Carpenter ZW, De Keersmaecker K, Sole X, Xu L, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Meijerink JP, Califano A, Ferrando AA.

Nat Med. 2012 Feb 26;18(3):436-40. doi: 10.1038/nm.2610.

29.

Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.

Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D, da Ros V, Tang Z, Siegle J, Asp P, Hadler M, Rigo I, De Keersmaecker K, Patel J, Huynh T, Utro F, Poglio S, Samon JB, Paietta E, Racevskis J, Rowe JM, Rabadan R, Levine RL, Brown S, Pflumio F, Dominguez M, Ferrando A, Aifantis I.

Nat Med. 2012 Feb 6;18(2):298-301. doi: 10.1038/nm.2651.

30.

The other Achilles' heel of BCR-ABL1.

De Keersmaecker K.

Haematologica. 2012 Jan;97(1):2. doi: 10.3324/haematol.2011.061002. No abstract available.

31.

TLX1-induced T-cell acute lymphoblastic leukemia.

De Keersmaecker K, Ferrando AA.

Clin Cancer Res. 2011 Oct 15;17(20):6381-6. doi: 10.1158/1078-0432.CCR-10-3037. Epub 2011 Jun 24.

32.

Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.

Schmidt T, Kharabi Masouleh B, Loges S, Cauwenberghs S, Fraisl P, Maes C, Jonckx B, De Keersmaecker K, Kleppe M, Tjwa M, Schenk T, Vinckier S, Fragoso R, De Mol M, Beel K, Dias S, Verfaillie C, Clark RE, Brümmendorf TH, Vandenberghe P, Rafii S, Holyoake T, Hochhaus A, Cools J, Karin M, Carmeliet G, Dewerchin M, Carmeliet P.

Cancer Cell. 2011 Jun 14;19(6):740-53. doi: 10.1016/j.ccr.2011.05.007.

33.

The TLX1 oncogene drives aneuploidy in T cell transformation.

De Keersmaecker K, Real PJ, Gatta GD, Palomero T, Sulis ML, Tosello V, Van Vlierberghe P, Barnes K, Castillo M, Sole X, Hadler M, Lenz J, Aplan PD, Kelliher M, Kee BL, Pandolfi PP, Kappes D, Gounari F, Petrie H, Van der Meulen J, Speleman F, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Soulier J, Avran D, Cavé H, Dastugue N, Raimondi S, Meijerink JP, Cordon-Cardo C, Califano A, Ferrando AA.

Nat Med. 2010 Nov;16(11):1321-7. doi: 10.1038/nm.2246. Epub 2010 Oct 24.

34.

Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia.

Hodson DJ, Janas ML, Galloway A, Bell SE, Andrews S, Li CM, Pannell R, Siebel CW, MacDonald HR, De Keersmaecker K, Ferrando AA, Grutz G, Turner M.

Nat Immunol. 2010 Aug;11(8):717-24. doi: 10.1038/ni.1901. Epub 2010 Jul 11. Erratum in: Nat Immunol. 2010 Oct;11(10):969.

35.

Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.

Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, Graux C, Van Roosbroeck K, Ferrando AA, Langerak AW, Meijerink JP, Sigaux F, Haferlach T, Wlodarska I, Vandenberghe P, Soulier J, Cools J.

Nat Genet. 2010 Jun;42(6):530-5. doi: 10.1038/ng.587. Epub 2010 May 16.

36.

Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia.

Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K, Zuber J, James T, Khan AA, Leslie CS, Parker JS, Paddison PJ, Tam W, Ferrando A, Wendel HG.

Nat Cell Biol. 2010 Apr;12(4):372-9. doi: 10.1038/ncb2037. Epub 2010 Feb 28.

37.

T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1.

Cortes J, De Keersmaecker K.

Leuk Lymphoma. 2009 Mar;50(3):321-2. doi: 10.1080/10428190902725821. No abstract available.

PMID:
19294558
38.

JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines.

Porcu M, Gielen O, Cools J, De Keersmaecker K.

Haematologica. 2009 Mar;94(3):435-7. doi: 10.3324/haematol.13587. Epub 2009 Jan 27. No abstract available.

39.

ABL1 fusions in T-cell acute lymphoblastic leukemia.

De Keersmaecker K.

Verh K Acad Geneeskd Belg. 2008;70(4):245-55. Review.

PMID:
19166098
40.

Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.

Graux C, Stevens-Kroef M, Lafage M, Dastugue N, Harrison CJ, Mugneret F, Bahloula K, Struski S, Grégoire MJ, Nadal N, Lippert E, Taviaux S, Simons A, Kuiper RP, Moorman AV, Barber K, Bosly A, Michaux L, Vandenberghe P, Lahortiga I, De Keersmaecker K, Wlodarska I, Cools J, Hagemeijer A, Poirel HA; Groupe Francophone de Cytogénétique Hématologique; Belgian Cytogenetic Group for Hematology and Oncology.

Leukemia. 2009 Jan;23(1):125-33. doi: 10.1038/leu.2008.278. Epub 2008 Oct 16.

PMID:
18923437
41.

Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.

De Keersmaecker K, Versele M, Cools J, Superti-Furga G, Hantschel O.

Leukemia. 2008 Dec;22(12):2208-16. doi: 10.1038/leu.2008.242. Epub 2008 Sep 11.

PMID:
18784740
42.

Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore.

De Keersmaecker K, Rocnik JL, Bernad R, Lee BH, Leeman D, Gielen O, Verachtert H, Folens C, Munck S, Marynen P, Fornerod M, Gilliland DG, Cools J.

Mol Cell. 2008 Jul 11;31(1):134-42. doi: 10.1016/j.molcel.2008.05.005.

43.

In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.

De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, Vandenberghe P, Odero MD, Marynen P, Cools J.

Haematologica. 2008 Apr;93(4):533-42. doi: 10.3324/haematol.11894. Epub 2008 Mar 5.

44.

Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.

Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, Mentens N, Beverloo HB, Pieters R, Speleman F, Odero MD, Bauters M, Froyen G, Marynen P, Vandenberghe P, Wlodarska I, Meijerink JP, Cools J.

Nat Genet. 2007 May;39(5):593-5. Epub 2007 Apr 15.

PMID:
17435759
45.

Transition from EML1-ABL1 to NUP214-ABL1 positivity in a patient with acute T-lymphoblastic leukemia.

De Keersmaecker K, Lahortiga I, Graux C, Marynen P, Maertens J, Cools J, Vandenberghe P.

Leukemia. 2006 Dec;20(12):2202-4. Epub 2006 Oct 5. No abstract available.

PMID:
17024111
46.

Chronic myeloproliferative disorders: a tyrosine kinase tale.

De Keersmaecker K, Cools J.

Leukemia. 2006 Feb;20(2):200-5. Review.

PMID:
16341034
47.

Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia.

De Keersmaecker K, Marynen P, Cools J.

Haematologica. 2005 Aug;90(8):1116-27. Review.

48.

Solvent-controlled organization of self-assembled polymeric monolayers on gold: an easy approach for the construction of protein resistant surfaces.

Zhou C, Khlestkin VK, Braeken D, De Keersmaecker K, Laureyn W, Engelborghs Y, Borghs G.

Langmuir. 2005 Jun 21;21(13):5988-96.

PMID:
15952851
49.

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).

De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, Wlodarska I, Vandenberghe P, Hagemeijer A, Marynen P, Cools J.

Blood. 2005 Jun 15;105(12):4849-52. Epub 2005 Feb 15.

50.

Implications of the use of neuromuscular transmission monitoring on immediate postoperative extubation in off-pump coronary artery bypass surgery.

Cammu G, De Keersmaecker K, Casselman F, Coddens J, Hendrickx J, Van Praet E, Deloof T.

Eur J Anaesthesiol. 2003 Nov;20(11):884-90.

PMID:
14649340

Supplemental Content

Loading ...
Support Center